UBS Group
PMVP icon

UBS Group’s PMV Pharmaceuticals PMVP Stock Holding History

UBS Group’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$448 Sell
361
-737
-67% -$937 ﹤0.01% 9891
2025
Q4 		$1.37K Sell
1,098
-453
-29% -$607 ﹤0.01% 9606
2025
Q3 		$2.17K Sell
1,551
-120,759
-99% -$167K ﹤0.01% 9210
2025
Q2 		$130K Sell
122,310
-29,973
-20% -$29.4K ﹤0.01% 7023
2025
Q1 		$166K Sell
152,283
-123,181
-45% -$167K ﹤0.01% 6667
2024
Q4 		$416K Buy
275,464
+96,598
+54% +$153K ﹤0.01% 5969
2024
Q3 		$267K Buy
178,866
+93,963
+111% +$145K ﹤0.01% 5661
2024
Q2 		$138K Sell
84,903
-48,721
-36% -$87.9K ﹤0.01% 5941
2024
Q1 		$227K Buy
133,624
+5,756
+5% +$10.8K ﹤0.01% 5771
2023
Q4 		$396K Sell
127,868
-15,813
-11% -$41.8K ﹤0.01% 5289
2023
Q3 		$882K Buy
143,681
+45,962
+47% +$316K ﹤0.01% 4187
2023
Q2 		$612K Buy
97,719
+8,075
+9% +$42.3K ﹤0.01% 4660
2023
Q1 		$428K Sell
89,644
-194,744
-68% -$1.37M ﹤0.01% 4811
2022
Q4 		$2.47M Buy
284,388
+164,543
+137% +$1.75M ﹤0.01% 3182
2022
Q3 		$1.43M Sell
119,845
-230,465
-66% -$3.33M ﹤0.01% 3453
2022
Q2 		$4.99M Buy
350,310
+161,299
+85% +$2.35M ﹤0.01% 2380
2022
Q1 		$3.94M Buy
189,011
+60,104
+47% +$1.06M ﹤0.01% 2777
2021
Q4 		$2.98M Buy
128,907
+32,869
+34% +$794K ﹤0.01% 3362
2021
Q3 		$2.86M Buy
96,038
+94,956
+8,776% +$3.03M ﹤0.01% 3249
2021
Q2 		$37K Sell
1,082
-11,857
-92% -$396K ﹤0.01% 6723
2021
Q1 		$426K Buy
12,939
+10,413
+412% +$410K ﹤0.01% 4995
2020
Q4 		$155K Buy
2,526
+1,955
+342% +$76.7K ﹤0.01% 5403
2020
Q3 		$20K Buy
+571
New +$21K ﹤0.01% 6312

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

UBS Group's PMVP Position: Q1 2026 in Review

UBS Group reduced its PMV Pharmaceuticals (PMVP) stake by 67% in Q1 2026, selling an estimated $937 and leaving 361 shares worth $448. The position accounts for ﹤0.01% of the portfolio, ranked #9891.

UBS Group first reported a position in PMVP in Q3 2020 and has held it in 23 quarters since. The position peaked at $4.99M in Q2 2022. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • UBS Group held 361 shares of PMV Pharmaceuticals worth $448 as of Q1 2026.
  • UBS Group sold 737 PMV Pharmaceuticals shares in Q1 2026, an estimated $937.
  • PMV Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9891 holding.
  • UBS Group first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 23 quarters since.
  • UBS Group's PMV Pharmaceuticals position peaked at $4.99M in Q2 2022.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.